Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Humacyte Inc (NQ: HUMA )

4.490 +0.110 (+2.51%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Humacyte Inc

< Previous 1 2 Next >
Humacyte, Inc. Shareholder Alert: Robbins LLP Reminds Investors of the HUMA Securities Class Action
From Robbins LLP
Via GlobeNewswire
HUMA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Humacyte, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Humacyte, Inc. (HUMA)
From Law Offices of Howard G. Smith
Via Business Wire
Faruqi & Faruqi Reminds Humacyte Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 – HUMA
From Faruqi & Faruqi LLP
Via GlobeNewswire
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Humacyte, Inc. (HUMA)
From Glancy Prongay & Murray LLP
Via Business Wire
HUMACYTE, INC. (NASDAQ: HUMA) INVESTOR ALERT: Investors With Large Losses in Humacyte, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte
From Faruqi & Faruqi, LLP
Via Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc. (HUMA) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Humacyte, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc. (HUMA) Investors
From Kirby McInerney LLP
Via Business Wire
Rosen Law Firm Urges Humacyte, Inc. (NASDAQ: HUMA) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc. (HUMA) Investors
From Law Offices of Howard G. Smith
Via Business Wire
HUMA CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Humacyte, Inc.
From Glancy Prongay & Murray LLP
Via Business Wire
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. is Investigating Humacyte, Inc. on Behalf of Humacyte Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
The Law Offices of Frank R. Cruz Continues Its Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. is Investigating Humacyte, Inc. on Behalf of Humacyte Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Humacyte, Inc. (HUMA)
From Kirby McInerney LLP
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Humacyte, Inc. (HUMA) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
InvestorNewsBreaks – EF Hutton Serves as Placement Agent to Humacyte Inc.’s (NASDAQ: HUMA) $30M RDO
Via Investor Brand Network
Kaplan Fox & Kilsheimer LLP is Investigating Humacyte, Inc. (HUMA) for Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
Kaplan Fox &amp; Kilsheimer LLP is Investigating Humacyte, Inc. (HUMA) for Potential Securities Law Violations
NEW YORK - (NewMediaWire) - October 22, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA). 
Via TheNewswire.com
Exposures Product Safety
Humacyte Is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
Humacyte Is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox &amp; Kilsheimer LLP
NEW YORK - (NewMediaWire) - October 21, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA). 
Via TheNewswire.com
Exposures Product Safety
Kaplan Fox & Kilsheimer LLP is Investigating Potential Securities Law Violations Against Humacyte, Inc. (HUMA)
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Exposures Product Safety
Kaplan Fox &amp; Kilsheimer LLP is Investigating Potential Securities Law Violations Against Humacyte, Inc. (HUMA)
NEW YORK, NY - (NewMediaWire) - October 19, 2024 - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA). 
Via TheNewswire.com
Exposures Product Safety
Pluristyx Announces License Agreement with Humacyte to Develop BioVascular Pancreas using iPSCs
From Pluristyx
Via Business Wire
Humacyte to Present at the Piper Sandler 35th Annual Healthcare Conference
From Humacyte, Inc
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.